Small Cap Stocks Worth Watching – August 1st

ProShares UltraPro Short QQQ, Focus Universal, Direxion Daily AMZN Bull 2X Shares, Direxion Daily MSFT Bull 2X Shares, and Replimune Group are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations, typically ranking below large- and mid-cap companies in size. They may offer greater growth potential, but they also tend to carry higher volatility and investment risk because smaller companies often have fewer resources and less-established businesses. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Focus Universal (FCUV)

Focus Universal Inc. develops and manufactures smart instrumentation platform and device. It offers Ubiquitor, a wireless sensor device with a universal sensor node and gateway system that uses a computer or mobile device as the output display module that displays the readings of various sensor nodes.

Direxion Daily AMZN Bull 2X Shares (AMZU)

Direxion Daily MSFT Bull 2X Shares (MSFU)

Replimune Group (REPL)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.